Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study

Clinical Pharmacokinetics

Volumn 56, Issue 1, 2017, Pages 41-54

  Glund, Stephan ^a   Stangier, Joachim ^a   van Ryn, Joanne ^a   Schmohl, Michael ^a   Moschetti, Viktoria ^a   Haazen, Wouter ^b   De Smet, Marina ^c   Gansser, Dietmar ^a   Norris, Stephen ^d   Lang, Benjamin ^a   Reilly, Paul ^d   Kreuzer, Jörg ^a,e  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b SGS Life Science Services   (Belgium)

^c Boehringer Ingelheim   (Belgium)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DABIGATRAN ETEXILATE; ECARIN; IDARUCIZUMAB; PLACEBO; ANTITHROMBIN; DABIGATRAN; MONOCLONAL ANTIBODY;

ADULT; AGE; AGED; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; CONTROLLED STUDY; CREATININE CLEARANCE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THROMBIN TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; URINARY EXCRETION; VERY ELDERLY; VOLUME OF DISTRIBUTION AT STEADY-STATE; BLOOD CLOTTING; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; HALF LIFE TIME; KIDNEY FAILURE; KIDNEY FUNCTION TEST; METABOLIC CLEARANCE RATE; METABOLISM; PHASE 1 CLINICAL TRIAL; TIME FACTOR;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTITHROMBINS; AREA UNDER CURVE; BLOOD COAGULATION; CROSS-OVER STUDIES; DABIGATRAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; KIDNEY FUNCTION TESTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RENAL INSUFFICIENCY; TIME FACTORS;

EID: 84975119946     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0417-0     Document Type: Article

References (17)

1. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.
2. Schulman S, Eriksson H, Kakkar A, et al. Influence of age and renal function on efficacy and safety of dabigatran versus warfarin for the treatment of acute venous thromboembolism: a pooled analysis of RE-COVER™ and RE-COVER™ II. Blood. 2014;121:594.
3. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342–52.
4. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764–72.
5. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–64.
6. Seeger JD, Bykov K, Bartels DB, et al. Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation. Thromb Haemost. 2015;114:1277–89.
7. Villines T, Schnee J, Fraeman K, et al. The comparative safety and effectiveness of the oral anticoagulant (OAC) dabigatran versus warfarin utilized in a large healthcare system in non-valvular atrial fibrillation (NVAF) patients. Circulation. 2014;130(Suppl 2):A18353.
8. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation. 2013;128:2325–32.
9. Sarich TC, Seltzer JH, Berkowitz SD, et al. Novel oral anticoagulants and reversal agents: considerations for clinical development. Am Heart J. 2015;169:751–7.
10. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121:3554–62.
11. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386:680–90.
12. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–51.
13. Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. Circulation. 2014;129:961–70.
14. Glund S, Stangier J, van Ryn J, et al. Re-starting dabigatran etexilate 24 hours after reversal with idarucizumab and re-dosing idarucizumab in healthy volunteers. J Am Coll Cardiol. 2016;67:1653–9.
15. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138–43.
16. Stangier J, Rathgen K, Stahle H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49:259–68.
17. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–20.